Successful treatment of choroidal neovascularization secondary to sorsby fundus dystrophy with intravitreal bevacizumab.

Objective: The purpose of this study was to investigate the response of choroidal neovascularization (CNV) in Sorsby fundus dystrophy to intravitreal bevacizumab.

Methods: Three eyes of 2 patients with CNV as a result of Sorsby fundus dystrophy were treated with intravitreal bevacizumab injections (0.05 mL, 1.25 mg bevacizumab). Best-corrected visual acuity, optical coherence tomography, and/or fluorescein angiography before and after treatment were assessed.

Results: At 33-month follow-up, after 6 intravitreal bevacizumab injections in 1 eye of the first patient, best-corrected visual acuity improved from 1.00 logarithm of the minimum angle of resolution to 0.93 logarithm of the minimum angle of resolution; there was no evidence of CNV activity on optical coherence tomography or on fluorescein angiography. At 6 weeks after 1 injection in the first patient's fellow eye, best-corrected visual acuity was stabilized at 0.00 logarithm of the minimum angle of resolution without any CNV activity on optical coherence tomography or on fluorescein angiography. At 12-week follow-up, after 1 intravitreal bevacizumab injection in 1 eye of the second patient, best-corrected visual acuity improved from 1.00 logarithm of the minimum angle of resolution to 0.00 logarithm of the minimum angle of resolution; there was no evidence of CNV activity on optical coherence tomography or on fluorescein angiography.

Conclusions: Intravitreal bevacizumab should be considered as a safe and effective treatment for CNV secondary to Sorsby fundus dystrophy.